This study is to evaluate the efficacy and safety of induction therapy with 2 doses of TD-1473 in patients with moderate-to-severe active Crohn?s Disease (CD). Designed to provide an alternative treatment for patients with CD to act directly at the site of inflammation in the intestinal wall, avoiding systemic effects.
Eligible participants must be male or female 18 years of age or older.
They must have at least 3 months prior history of CD, have been diagnosed by a physician with CD, present with CD symptoms and have had an inadequate response, loss of response or intolerance to a treatment for CD.